LDC000067

LDC000067 Basic information
Product Name:LDC000067
Synonyms:LDC000067;LDC 067;LDC067;LDC-067;(3-(6-(2-Methoxyphenyl)pyrimidin-4-ylamino)phenyl)methanesulfonamide;3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-benzenemethanesulfonamide;LDC067;LDC 000067;LDC-000067;LDC 067;LDC-067;CS-1535
CAS:1073485-20-7
MF:C18H18N4O3S
MW:370.43
EINECS:
Product Categories:Inhibitors;API
Mol File:1073485-20-7.mol
LDC000067 Structure
LDC000067 Chemical Properties
Boiling point 604.1±65.0 °C(Predicted)
density 1.360±0.06 g/cm3(Predicted)
storage temp. under inert gas (nitrogen or Argon) at 2–8 °C
solubility insoluble in H2O; insoluble in EtOH; ≥18.52 mg/mL in DMSO
form Powder
pka10.27±0.60(Predicted)
Safety Information
MSDS Information
LDC000067 Usage And Synthesis
Biological Activityldc000067 (ldc067) is a novel specific inhibitor of cdk9 with ic50 value of 44 ± 10 nm [1].cyclin-dependent kinase 9 (cdk9) is a cyclin-dependent kinase. cdk9 and cyclin t form the positive transcription elongation factor b (p-tefb) complex for rna polymerase ii and functions by phosphorylating the c-terminal domain of the largest subunit of rna polymerase ii [1].ldc000067 (ldc067) is a novel and highly specific cdk9 inhibitor. ldc000067 exhibited selectivity for cdk9 over other cdks in the range of 55-fold (vs. cdk2) to over 230-fold (vs. cdk6 and cdk7). ldc067 also inhibited transcription in a dose-dependent and atp-competitive manner. in whole cells, ldc000067 induced the tumor suppressor protein p53 activation and apoptosis. ldc000067 also selectively reduced short-lived mrnas, including those that encode regulators of apoptosis and proliferation such as myc and mcl1 [1].
in vitro

LDC000067 reduces Ser2-P in mESCs, induces p53 activation, and leads to apoptosis. In addition, LDC067 also dose-dependently inhibited the de novo RNA synthesis of P-TEFb-dependent cellular genes.

target
TargetValue
CDK9
(Cell-free assay)
44 nM
CDK2
(Cell-free assay)
2.441 μM
storageStore at -20°C
references[1]. albert tk, rigault c, eickhoff j, et al. characterization of molecular and cellular functions of the cyclin-dependent kinase cdk9 using a novel specific inhibitor. br j pharmacol, 2014, 171(1): 55-68.
LDC000067 Preparation Products And Raw materials
Raw materials4-Chloro-6-(2-methoxy-phenyl)-pyrimidine-->(3-AMINO-PHENYL)-METHANESULFONAMIDE
PHA 767491 HYDROCHLORIDE Abemaciclib mesylate (LY2835219) (2S)-1-[3-Ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-2-piperidineethanol BS-181 HCl Ribociclib Sulfadiazine Pictilisib Diphenhydramine p-Anisidine

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.